Compare Gilead Sciences, Inc. (GILD) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SoFi Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $134.82 (market cap $163.51B), while SoFi Technologies Inc trades at $17.36 (market cap $22.92B). The key difference: Gilead Sciences, Inc. is far larger — about 7.1× SoFi Technologies Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals.
| GILD | SOFI | |
|---|---|---|
Market Cap | $163.51B | $22.92B |
Sector | Health | Financials |
52-Week High | $155.80 | $32.21 |
52-Week Low | $108.22 | $15.15 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
SOFI stock trades at $17.60, down 5.12% on the day, reflecting recent market pressures. The technical outlook is neutral with mixed signals, while fundamentals show robust revenue growth to $3.61 billion in 2025 and consistent earnings beats. Analyst sentiment is divided with a consensus price target of $22.43, but the stock faces headwinds from negative operating cash flow and high valuation multiples.
The investment case hinges on SOFI's ability to sustain top-line expansion and improve cash flow generation. Near-term catalysts include Q2 2026 earnings on July 29, where management guides for 30% revenue growth. Key risks involve persistent cash burn, competitive intensity in fintech, and sensitivity to interest rate changes. The stock offers upside to consensus targets if execution remains strong.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
